Lynk Pharmaceuticals Reports Positive Long-Term Phase III Zemprocitinib Results
Lynk Pharmaceuticals reported positive long-term Phase III results for zemprocitinib in bDMARD-inadequate responders with moderate-to-severe rheumatoid arthritis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Zemprocitinib Results
Lynk Pharmaceuticals reported positive long-term Phase III results for zemprocitinib in bDMARD-inadequate responders with moderate-to-severe rheumatoid arthritis.